Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01597024
Other study ID # Full4Health
Secondary ID
Status Completed
Phase N/A
First received May 7, 2012
Last updated May 19, 2016
Start date May 2012
Est. completion date October 2015

Study information

Verified date May 2016
Source University of Aberdeen
Contact n/a
Is FDA regulated No
Health authority United Kingdom: National Health ServiceUnited Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

The primary aim of this work is, to 'relate psychological and behavioural parameters of hunger/satiety and food preference to gut hormones, neural activation and energy metabolism by dietary manipulation, across the human lifespan'.


Description:

The Full4Health project aims to further understanding of the mechanisms of hunger and satiety. The proposal integrates investigation of human volunteers and laboratory rodents throughout the life course, applying imaging and other cutting edge technologies to critical research questions. Full4Health will combine study of the mechanisms of hunger and satiety with intervention studies to validate the effects of the relevant food characteristics on the regulation of satiety/hunger. The development of cerebral responses to food through the gut-brain axis across lifespan particularly during childhood, adolescence and elderly will be studied.


Recruitment information / eligibility

Status Completed
Enrollment 718
Est. completion date October 2015
Est. primary completion date August 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 8 Years to 75 Years
Eligibility Inclusion Criteria:

- Willingness to participate in the fMRI study

- Right-handed

- Not heavy smokers (less 10 day)

- MRI compatibility:

- no claustrophobia

- no metal in the body (including dental braces)

Exclusion Criteria:

- Heavy smokers (more than 10/day)

- Morbid obese (BMI>40 kg/m2)

- Pregnancy

- Obesity of known endocrine origin

- Neurological disorders including Cerebral Palsy

- Alzheimers disease

- Multiple Sclerosis

- Parkinsons disease

- Medication known to influence appetite (orlistat, oral antidiabetics, insulin, digoxin, anti-arrhythmics, sibutramine, antidepressants)

- Self report fever/systemic infection

- Inability to participate in fMRI scanning sessions including contraindications to MRI

- Participation in medical or surgical weight loss programme within 1 month of selection

- History of cerebrovascular disease

- Current major depressive disorder, bipolar disorder or past history of suicide attempt or self harm

- History of drug or alcohol misuse

- History of significant cardiovascular disease

- Allergy to any of the breakfasts components.

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Other:
Breakfast Study
Participants (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and appetite. Biomarkers in blood will be measured and behavioural questionnaires completed. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There will be two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Participants will be offered a morning snack buffet to assess ad libitum energy intake. Phase 1 will also include a subgroup of malnourished male and female elderly participants. However, this group will only complete two morning sessions during which they will consume a low protein and a high protein milk based beverage. Appetite will be recorded and libitum energy intake will be measured. In addition, 24hr energy intake will be recorded.
fMRI Study
We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Participants will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The participants will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.

Locations

Country Name City State
Greece Harokopia Univeristy Athens
Netherlands University Medical Center Utrecht Utrecht
United Kingdom The Rowett Institute of Nutrition and Health, University of Aberdeen Aberdeen Aberdeenshire

Sponsors (2)

Lead Sponsor Collaborator
University of Aberdeen European Union

Countries where clinical trial is conducted

Greece,  Netherlands,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in concentrations of biomarkers of appetite in response to each milk-based beverage The following blood-borne biomarkers of appetite will be measured:
Glucose
Total cholesterol
Triglycerides
Low density lipoprotein
High density lipoprotein
Insulin
Ghrelin (active)
Glucagon-like peptide-1 (active)
Peptide YY (total)
Leptin
During each of the four 'Breakfast Study' visits blood will be taken at baseline, and 30, 60, and 120 minutes after consuming the milk-based beverage. Each visit will be seperated by one week. No
Secondary Neural responses to images of food when fasted and after consuming a milk-based beverage The subjects will conduct a computerised task that will be performed in the functional magnetic resonance imaging (fMRI) scanner. Subjects will be measured twice, on separate days, either after an overnight fast or after a test meal fed to satiation. There will be one week between both conditions (fasted and fed) No
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2

External Links